tirzepatide shortage resolved Resolved? FDA Says Yes, Compounders No FDA Response to Shortage Notification

The online discussion, which took place before the Food and Drug Administration (FDA) approved tirzepatide for the treatment of patients with sleep apnea in December of 2024, is available to watch here .Heres what you need to know

Experts said broader physician uptake, improved availability, and relatively lower pricing versus competition are helping semaglutide close the gap

Brand-name Ozempic without assistance: $17,442 (18 months at $969/month) Brand-name Ozempic with maximum savings card benefit (best-case scenario for commercially insured): $450 (18 months at $25/month assuming you qualify and maintain eligibility) Compounded semaglutide: $3,582 (18 months at $199/month) The cost difference between brand-name without assistance and compounded alternatives is $13,860 over 18 months

There are few GLP-1 agonists available around the world